ZEO ScientifiX

ZEO ScientifiX, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of biological therapeutics for the treatment of degenerative diseases. The company is headquartered in Davie, Florida and currently employs 20 full-time employees. The company went IPO on 2013-11-08. The firm is primarily focused on developing innovative biological therapeutics for regenerative medicine and the treatment of degenerative diseases. Its proprietary products, including Zofin, which are derived from perinatal sources and manufactured to retain the naturally occurring extracellular vesicles, proteins and cell secreted nanoparticles, and Patient Pure X (PPX), an autologous biologic containing a nanoparticle fraction that is precipitated from a patient’s own peripheral blood (RAAM Products). Its RAAM Products and related services are principally used in the health care industry administered through doctors and clinics. The company has developed and begun to distribute additional products that incorporate its proprietary ingredients for products to be used in topical aesthetic applications and is actively exploring further development of additional products to be used in other topical aesthetic applications.